Precigen Inc

PGEN has transitioned into a Stage 3 distribution phase with lower highs and failed EMA rallies confirming medium-term bearish bias. Short-term momentum remains weak under declining 9/21 EMAs, making immediate selling less opportune. Trimming into rallies around the 9EMA, 20EMA, and 50DMA resistance zone offers disciplined engagement. Key risks include a sharp bounce trapping sellers and an accelerated breakdown into Stage 4 distribution.

• ↑FDA orphan exclusivity secures seven-year protection for PAPZIMEOS.
• ↑Q1 2026 revenue expected >$18 M after FY 2025 sales rose to $9.7 M (+149% YoY).
• ↓Negative earnings yield and profitability factors signal long-term viability risks.